Paratek Pharmaceuticals’ Shares Gain Following FDA Fast Track Designation For Nontuberculous Mycobacterial (NTM) Drug
Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) received Fast Track designation from the U.S.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
Looking Into Paratek Pharmaceuticals’s Return On Capital Employed
Benzinga Pro data, Paratek Pharmaceuticals (NASDAQ:PRTK) reported Q4 sales of $31.80 million. Earnings fell to a loss of $32.25 million, resulting in a 77.19% decrease from last quarter.
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell
• F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Paratek Pharmaceuticals’s Earnings: A Preview
Paratek Pharmaceuticals (NASDAQ:PRTK) is set to give its latest quarterly earnings report on Monday, 2022-03-14. Here's what investors need to know before the announcement.
Analysts estimate that Paratek Pharmaceuticals will report an earnings per share (EPS) of $-0.41.
